Details for New Drug Application (NDA): 208255
✉ Email this page to a colleague
The generic ingredient in SYMFI LO is efavirenz; lamivudine; tenofovir disoproxil fumarate. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the efavirenz; lamivudine; tenofovir disoproxil fumarate profile page.
Summary for 208255
| Tradename: | SYMFI LO |
| Applicant: | Mylan |
| Ingredient: | efavirenz; lamivudine; tenofovir disoproxil fumarate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 400MG;300MG;300MG | ||||
| Approval Date: | Feb 5, 2018 | TE: | AB | RLD: | Yes | ||||
Complete Access Available with Subscription
